

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司 *
KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9939)

INSIDE INFORMATION

**RESULTS OF KX-826 PHASE III CLINICAL TRIAL FOR TREATMENT OF
MALE AGA IN CHINA**

This announcement is made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and the Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited.

The board (the “**Board**”) of directors (the “**Directors**”) announces that the topline results of phase III clinical trial (the “**Phase III Clinical Trial**”) of KX-826 topical treatment for male androgenetic alopecia (the “**AGA**”) have been read out. This Phase III Clinical Trial is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topical use of KX-826 twice daily at a concentration of 0.5% in the treatment of male AGA adults in China. The main endpoint of this study is the average change in non-vellus target area hair counts (the “**TAHC**”) compared to baseline at the end of 24 weeks. Safety endpoints include the type, incidence, and severity of adverse events.

The results showed that the overall safety of the trial was good, with KX-826 demonstrating excellent safety profile and no serious adverse events was reported. After 24 weeks’ treatment,

TAHC of the treatment group showed that KX-826 promoted hair growth compared to baseline, with statistical significance ($P < 0.0001$). Compared with placebo, there was TAHC improvement at all visit points in KX-826 group with no statistical significance, but a trend in efficacy was observed.

The Company will continue to analyze the results of the Phase III Clinical Trial in the future, and the group will further conduct multiple clinical trials of KX-826 for topical treatment of AGA and acne, exploring the possibility of the commercialization of KX-826.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that KX-826 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, 27 November 2023

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong, Dr. Qun Lu and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*